The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration

Autor: Thomas Senage, Anu Paul, Thierry Le Tourneau, Imen Fellah-Hebia, Marta Vadori, Salam Bashir, Manuel Galiñanes, Tomaso Bottio, Gino Gerosa, Arturo Evangelista, Luigi P. Badano, Alberto Nassi, Cristina Costa, Galli Cesare, Rizwan A. Manji, Caroline Cueff de Monchy, Nicolas Piriou, Romain Capoulade, Jean-Michel Serfaty, Guillaume Guimbretière, Etienne Dantan, Alejandro Ruiz-Majoral, Guénola Coste du Fou, Shani Leviatan Ben-Arye, Liana Govani, Sharon Yehuda, Shirley Bachar Abramovitch, Ron Amon, Eliran Moshe Reuven, Yafit Atiya-Nasagi, Hai Yu, Laura Iop, Kelly Casós, Sebastián G. Kuguel, Arnau Blasco-Lucas, Eduard Permanyer, Fabrizio Sbraga, Roger Llatjós, Gabriel Moreno-Gonzalez, Melchor Sánchez-Martínez, Michael E. Breimer, Jan Holgersson, Susann Teneberg, Marta Pascual-Gilabert, Alfons Nonell-Canals, Yasuhiro Takeuchi, Xi Chen, Rafael Mañez, Jean-Christian Roussel, Jean-Paul Soulillou, Emanuele Cozzi, Vered Padler-Karavani
Přispěvatelé: unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Tel Aviv University (TAU), Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), Università degli Studi di Padova = University of Padua (Unipd), Universitat Autònoma de Barcelona (UAB), Vall d'Hebron University Hospital [Barcelona], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Llobregat Hospital [Barcelona], Fondazione Avantea [Cremona, Italy], St. Boniface Hospital Albrechtsen Research Centre [Winnipeg], Israel Institute for Biological Research (IIBR), University of California [Davis] (UC Davis), University of California (UC), Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), Quironsalud Teknon Heart Institute [Barcelona, Spain] (QTHI), Mind the Byte [Barcelona, Spain], Molomics [Barcelona, Spain], Sahlgrenska Academy at University of Gothenburg [Göteborg], Institut Universitari de Ciència i Tecnologia [Barcelona, Spain] ((Inkemia Group) IUCT), DevsHealth [Barcelona, Spain] (DH), University College of London [London] (UCL), Bellvitge University Hospital [Barcelona, Spain], Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Dantan, Etienne, Senage, T, Paul, A, Le Tourneau, T, Fellah-Hebia, I, Vadori, M, Bashir, S, Galinanes, M, Bottio, T, Gerosa, G, Evangelista, A, Badano, L, Nassi, A, Costa, C, Cesare, G, Manji, R, Cueff de Monchy, C, Piriou, N, Capoulade, R, Serfaty, J, Guimbretiere, G, Dantan, E, Ruiz-Majoral, A, Coste du Fou, G, Leviatan Ben-Arye, S, Govani, L, Yehuda, S, Bachar Abramovitch, S, Amon, R, Reuven, E, Atiya-Nasagi, Y, Yu, H, Iop, L, Casos, K, Kuguel, S, Blasco-Lucas, A, Permanyer, E, Sbraga, F, Llatjos, R, Moreno-Gonzalez, G, Sanchez-Martinez, M, Breimer, M, Holgersson, J, Teneberg, S, Pascual-Gilabert, M, Nonell-Canals, A, Takeuchi, Y, Chen, X, Manez, R, Roussel, J, Soulillou, J, Cozzi, E, Padler-Karavani, V, Institut Català de la Salut, [Senage T] Institut du Thorax, Institut National de la Santé et de la Recherche Médicale UMR1087, University Hospital, Nantes, France. Institut National de la Santé et de la Recherche Médicale UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France. [Paul A] Department of Cell Research and Immunology, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. [Le Tourneau T, Fellah-Hebia I] Institut du Thorax, Institut National de la Santé et de la Recherche Médicale UMR1087, University Hospital, Nantes, France. [Vadori M] Consortium for Research in Organ Transplantation, Ospedale Giustinianeo, Padova, Italy. [Bashir S] Department of Cell Research and Immunology, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. [Galiñanes M] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Evangelista A] Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Casós K] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Infectious Diseases and Transplantation Division, Institut d’Investigació Biomèdica de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Blasco-Lucas A] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Cardiac Surgery Department, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain. [Permanyer E] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Cardiac Surgery, Quironsalud Teknon Heart Institute, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
Rok vydání: 2021
Předmět:
[SDV]Life Sciences [q-bio]
Immunology
enfermedades cardiovasculares::enfermedades cardíacas [ENFERMEDADES]
Cardiovascular
Medical and Health Sciences
General Biochemistry
Genetics and Molecular Biology

Mice
Polysaccharides
Animals
Humans
Prospective Studies
Polysaccharide
Bioprosthesi
Bioprosthesis
5.3 Medical devices
Animal
Calcinosis
Galactose
Otros calificadores::Otros calificadores::/cirugía [Otros calificadores]
MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE
General Medicine
Aortic Valve Stenosis
Aortic Valve Stenosi
Other subheadings::Other subheadings::/surgery [Other subheadings]
Vàlvula aòrtica - Cirurgia
[SDV] Life Sciences [q-bio]
Cardiovascular Diseases::Heart Diseases [DISEASES]
Prospective Studie
Heart Disease
Aortic Valve
Immunoglobulin G
Antibody Formation
Calcinosi
Development of treatments and therapeutic interventions
Immunoglobulines
Human
Zdroj: NATURE MEDICINE
Nature Medicine
Nature Medicine, 2022, Online ahead of print. ⟨10.1038/s41591-022-01682-w⟩
Nature medicine, vol 28, iss 2
Scientia
ISSN: 1546-170X
1078-8956
1744-7933
DOI: 10.1038/s41591-022-01682-w⟩
Popis: Outcomes research; Risk factors Investigación de resultados; Factores de riesgo Recerca dels resultats; Factors de risc Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-α1,3-galactose (αGal) and N-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 ± 43 months of follow-up (0.1–182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in
Databáze: OpenAIRE